Massive study: Weight-Loss drug semaglutide slashes heart risks in real world
NCT ID NCT07141914
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 23 times
Summary
This study looked at over 285,000 people with overweight or obesity to see if the weekly injection semaglutide (used for weight loss and diabetes) lowers the risk of heart problems like heart attacks, strokes, and death. Researchers analyzed medical records from 2016 to 2024. The goal was to understand how well the drug works in everyday life, not just in controlled trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novo Nordisk Investigational
Plainsboro, New Jersey, 08536, United States
Conditions
Explore the condition pages connected to this study.